Pharmaceuticals

AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmologic, neurological and psychiat...

2023-09-20 09:00 2520

Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, announced today that the Center for Drug E...

2023-09-20 08:26 1984

Cerecin strengthens position in neurometabolism with addition to pipeline

* Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and usein positron emission tomography (PET) studies of ketone body metabolism * Company expands ketogenic platform following pilot data of CER-0001 in migraine and infantile spasms. ...

2023-09-19 19:39 1755

Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment

TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway), a biopharmaceutical company focusing on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage...

2023-09-19 11:16 1297

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities. The current expansion is in response to the growing demand...

2023-09-19 09:16 2020

Canton Biologics Completes Over 300 Million Yuan Series C Financing, Led by SDIC Venture Capital

GUANGZHOU, China, Sept. 18, 2023 /PRNewswire/ -- On September 13th, Canton Biologics Co., Ltd. announced that it had recently completed a Series C financing round exceeding300 million yuan. This round of financing was led by SDIC Venture Capital, with participation from Guangdong Technology Finan...

2023-09-18 18:43 2225

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

SINGAPORE, Sept. 18, 2023 /PRNewswire/ -- On September 14, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") was the recipient of the prestigious "Most Promising Cell Therapy Pipeline in APAC" award at the 7th Annual Cell & Gene Therapy World Asia 2023, amidst a pool of internation...

2023-09-18 17:53 2259

Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

INCHEON, South Korea, Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Bristol Myers Squibb and Samsung Biolog...

2023-09-18 07:57 1542

New drug class prevents key ageing mechanism in organ transplants

ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ -- A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs.  The pioneering research, presented today at the European Societ...

2023-09-18 06:01 1761

YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection

GAITHERSBURG, Md., Sept. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2023-09-15 20:30 2386

Neoss® Group has launched a new wireless intraoral scanner, NeoScan™ 2000

ZURICH, Sept. 15, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce the fast and easy-to-use wireless intraoral scanner, NeoScan™ 2000. This follows the success of last year's launch of the NeoScan™ 1000.

2023-09-15 16:00 2012

Green Leadership Award Presented to Chugai Pharma Taiwan at the Asia Responsible Enterprise Awards 2023

SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2023 is pleased to honor 30 outstanding business leaders and enterprises for championing sustainable and responsible business practices. Presented by leading regional NGO Enterprise Asia, the AREA is the mo...

2023-09-15 11:37 1882

MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study

GENEVA, Sept. 15, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimu...

2023-09-15 08:00 2119

Cure Genetics and Frametact Reach a $60 Million Collaboration and Licensing Agreement for the Development of Gene Therapy for Familial Neurological Diseases

SUZHOU, China and HONG KONG, Sept. 14, 2023 /PRNewswire/ -- Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement. The partnership ...

2023-09-14 23:00 1978

Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing ...

2023-09-14 20:00 1563

Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of Gene and Cell Therapies

SUZHOU, China, Sept. 14, 2023 /PRNewswire/ -- On September 13th, 2023, Porton Advanced Solutions (Porton Advanced) announced a strategic partnership with BRL Medicine Inc. (BRL Medicine). This collaboration will enhance the cell and gene therapy pipelines from BRL Medicine from clinical trials to...

2023-09-14 20:00 1975

Foundry Mixer Healthcare, Indonesian Minister of Health Budi G. Sadikin: "Together We Leapfrog Indonesia's Healthcare Transformation"

Indonesian Minister of Health, Budi Gunadi Sadikin, emphasized that investing in the Health Technology and Biotechnology sector serves not only business prospects but also strengthens Indonesia's health resilience and adds value to healthcare. JAKARTA, Indonesia, Sept. 14, 2023 /PRNewswire/ -- F...

2023-09-14 17:47 1740

Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphom...

2023-09-14 17:07 1620

Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC

SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its oral drug APL-1401 for the tr...

2023-09-14 16:54 1567

Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene

CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I™), announced an agreeme...

2023-09-14 16:00 1508
1 ... 89909192939495 ... 320